X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (493) 493
Publication (55) 55
Book Chapter (19) 19
Book Review (11) 11
Conference Proceeding (2) 2
Dissertation (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (254) 254
humans (225) 225
molecularly targeted therapy (166) 166
oncology (160) 160
cancer (141) 141
molecularly targeted agents (90) 90
chemotherapy (82) 82
antineoplastic agents - therapeutic use (66) 66
animals (65) 65
pharmacology & pharmacy (62) 62
molecularly imprinted polymers (56) 56
neoplasms - drug therapy (54) 54
clinical trials (53) 53
polymers (52) 52
female (48) 48
nanoparticles (48) 48
care and treatment (46) 46
molecular targeted therapy (45) 45
research (44) 44
chemistry, analytical (40) 40
tumors (40) 40
article (39) 39
drug delivery systems (39) 39
analysis (38) 38
drugs (36) 36
review (36) 36
male (35) 35
molecularly imprinted polymer (35) 35
health aspects (34) 34
metastasis (34) 34
toxicity (34) 34
treatment outcome (33) 33
molecular imprinting (32) 32
phase-ii trial (32) 32
antineoplastic agents - pharmacology (31) 31
cell lung-cancer (31) 31
immunotherapy (31) 31
middle aged (31) 31
recognition (31) 31
survival (30) 30
aged (28) 28
chemistry, multidisciplinary (28) 28
drug therapy (28) 28
therapy (28) 28
adult (27) 27
solid-phase extraction (27) 27
tyrosine kinase inhibitor (27) 27
antineoplastic agents - administration & dosage (26) 26
mice (26) 26
mip (26) 26
cancer therapies (25) 25
drug-delivery (25) 25
patients (25) 25
biomarkers (24) 24
hematology, oncology and palliative medicine (24) 24
radiotherapy (24) 24
antineoplastic agents - adverse effects (23) 23
biochemistry & molecular biology (23) 23
chemistry (23) 23
polymerization (23) 23
antineoplastic agents (22) 22
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
cell line, tumor (22) 22
clinical trials as topic (22) 22
clinical-trials (22) 22
hepatocellular carcinoma (22) 22
inhibitor (22) 22
medicine & public health (22) 22
molecular targeted therapy - methods (22) 22
molecularly targeted therapies (22) 22
bevacizumab (21) 21
drug delivery (21) 21
imprinted polymers (21) 21
medical research (21) 21
polymer industry (21) 21
sorafenib (21) 21
continual reassessment method (20) 20
lung cancer (20) 20
open-label (20) 20
prognosis (20) 20
proteins (20) 20
apoptosis (19) 19
breast-cancer (19) 19
dose-response relationship, drug (19) 19
maximum tolerated dose (19) 19
antimitotic agents (18) 18
efficacy (18) 18
hematology (18) 18
in-vitro (18) 18
separation (18) 18
adsorption (17) 17
combination (17) 17
growth-factor receptor (17) 17
imatinib mesylate (17) 17
medicine, research & experimental (17) 17
melanoma (17) 17
molecularly-imprinted-polymers (17) 17
surgery (17) 17
usage (17) 17
angiogenesis (16) 16
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (490) 490
Japanese (17) 17
German (7) 7
French (3) 3
Italian (2) 2
Polish (2) 2
Chinese (1) 1
Czech (1) 1
Hungarian (1) 1
Korean (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2017, Volume 16, Issue 10, pp. 2234 - 2245
Molecularly targeted drugs have yielded significant therapeutic advances in oncogene-driven non-small cell lung cancer (NSCLC), but a majority of patients... 
BREAST-CANCER | EGFR INHIBITORS | ONCOSTATIN M RECEPTOR | MELANOMA | ONCOLOGY | STAT3 | ACQUIRED-RESISTANCE | KINASE INHIBITORS | GROWTH-FACTOR | INTERLEUKIN-6 | GLPG0634 | Interleukin-6 - antagonists & inhibitors | Apoptosis - drug effects | Cancer-Associated Fibroblasts - metabolism | Humans | Middle Aged | Male | Epithelial-Mesenchymal Transition - genetics | Molecular Targeted Therapy | Oncostatin M - antagonists & inhibitors | Janus Kinase 1 - genetics | Female | Gene Expression Regulation, Neoplastic - drug effects | Cytokines - genetics | STAT3 Transcription Factor - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Interleukin-6 - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Janus Kinase 1 - antagonists & inhibitors | Cancer-Associated Fibroblasts - pathology | Drug Resistance, Neoplasm - genetics | Receptors, Oncostatin M - genetics | Signal Transduction - drug effects | Cell Line, Tumor | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Cytokines - antagonists & inhibitors | Neoplasm Staging | STAT3 Transcription Factor - antagonists & inhibitors | Oncostatin M - genetics | Drugs | Adenocarcinoma | Cytokines | Mesenchyme | Lung cancer | Stat3 protein | Paracrine signalling | Non-small cell lung carcinoma | Activation | Inflammation | Drug resistance | Drug development | Gene expression | Patients | Interleukin 6 | Receptors | Lungs | Fibroblasts | Janus kinase | Target acquisition | Cancer | Apoptosis | non-small cell lung cancer | proinflammatory cytokines | drug resistance | molecularly targeted therapy | epithelial-to-mesenchymal transition
Journal Article
Japanese Dental Science Review, ISSN 1882-7616, 05/2018, Volume 54, Issue 2, pp. 88 - 103
Human cancer tissues are heterogeneous in nature and become differentiated during expansion of cancer stem cells (CSCs). CSCs initiate tumorigenesis, and are... 
Molecularly-targeted therapy | Lapatinib | Oral squamous cell carcinoma | Cancer stem cells | Cetuximab | Sphere formation | Epidermal growth factor receptor | Review
Journal Article
细胞研究:英文版, ISSN 1001-0602, 2014, Volume 24, Issue 5, pp. 542 - 559
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 2017, Volume 28, Issue 10, pp. 1141 - 1149
Promising clinical efficacy has been observed with receptor tyrosine kinase inhibitors (TKIs) particularly in lung and gastric cancers with mutations or... 
Bcl-2 | lung cancer | Bcl-xL | gastric cancer | receptor tyrosine kinase | tyrosine kinase inhibitor | molecularly targeted therapy | ACTIVATION | IDENTIFY | EFFICACY | ACQUIRED-RESISTANCE | SENSITIVITY | INHIBITION | ONCOLOGY | GROWTH | GENE AMPLIFICATION | PHARMACOLOGY & PHARMACY | MUTATIONS | MET | Lung Neoplasms - drug therapy | Up-Regulation | Humans | Lung Neoplasms - metabolism | Stomach Neoplasms - metabolism | Drug Resistance, Neoplasm | Male | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Proto-Oncogene Proteins c-bcl-2 - metabolism | bcl-X Protein - antagonists & inhibitors | Aniline Compounds - administration & dosage | Stomach Neoplasms - enzymology | Aniline Compounds - pharmacology | Lung Neoplasms - enzymology | Random Allocation | Stomach Neoplasms - drug therapy | Sulfonamides - pharmacology | Drug Synergism | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | MAP Kinase Signaling System - drug effects | Mice, Nude | Cell Line, Tumor | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Mice | Protein Kinase Inhibitors - pharmacology | bcl-X Protein - metabolism | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Sulfonamides - administration & dosage | Tyrosine | Care and treatment | Research | Stomach cancer | Health aspects | Apoptosis | Receptor tyrosine kinase
Journal Article
Respiratory Investigation, ISSN 2212-5345, 01/2019, Volume 57, Issue 1, pp. 20 - 26
The discovery of oncogenic driver gene mutations, including epidermal growth factor receptor ( ) mutation, anaplastic lymphoma kinase ( ) fusion, ROS... 
ALK | Acquired resistance | Lung cancer | Molecularly targeted therapy | EGFR | Molecular targeted therapy | Care and treatment | Analysis | Genetic aspects | Research | Drug resistance
Journal Article